Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bimatoprost in Graves' Periorbitopathy
NCT03708627Phase 1Recruiting
- Sponsor
- Johns Hopkins University
- Start
- Nov 2017
- Primary completion
- Jul 2029
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label trial of bimatoprost in Graves' ophthalmopathy (TED) (2 arms), sponsored by Johns Hopkins University. Primary endpoint: Reduction in periorbital fat causing improvement in proptosis at 1 year. Started Nov 2017; status: recruiting.
02
Drugs
bimatoprost
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on NCT03708627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708627.